Literature DB >> 19111800

Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA).

Stacy Loeb1, Sara N Gashti, William J Catalona.   

Abstract

Prostate inflammation can lead to an elevation in the serum PSA concentration and confound the use of PSA kinetics. This can have considerable clinical consequences, since these measurements form the basis for important clinical decisions. Thus, there has been investigation into ways to decrease the confounding from inflammation, including repeat PSA measurements after a period of observation or a course of empiric antibiotics. This article reviews the evidence about elevations in PSA due to prostatitis and describes the controversy over the optimal approach to reduce its confounding impact on prostate cancer screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19111800     DOI: 10.1016/j.urolonc.2008.04.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  13 in total

Review 1.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

2.  Screening for prostate cancer: a controversy or fact.

Authors:  S Stavridis; S Saidi; Lj Lekovski; S Dohcev; G Spasovski
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

Review 3.  Screening for cancer with molecular markers: progress comes with potential problems.

Authors:  John A Baron
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

Review 4.  Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis.

Authors:  Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

5.  Small integrin-binding proteins as serum markers for prostate cancer detection.

Authors:  Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 6.  The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?

Authors:  Marianne Schmid; Quoc-Dien Trinh; Markus Graefen; Margit Fisch; Felix K Chun; Jens Hansen
Journal:  World J Urol       Date:  2014-05-14       Impact factor: 4.226

7.  Mean Platelet Volume-A Predictive Factor for the Diagnosis of Nonsymptomatic Prostatitis: Results of Univariate and Multivariate Models.

Authors:  Murat Mehmet Rifaioglu; Onur Demirbas; Hasan Gokce; Mursel Davarci
Journal:  Am J Mens Health       Date:  2016-07-08

8.  Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer.

Authors:  Fubo Wang; Shancheng Ren; Rui Chen; Ji Lu; Xiaolei Shi; Yasheng Zhu; Wei Zhang; Taile Jing; Chao Zhang; Jian Shen; Chuanliang Xu; Huiqing Wang; Haifeng Wang; Yang Wang; Bin Liu; Yaoming Li; Ziyu Fang; Fei Guo; Meng Qiao; Chengyao Wu; Qiang Wei; Danfeng Xu; Dan Shen; Xin Lu; Xu Gao; Jianguo Hou; Yinghao Sun
Journal:  Oncotarget       Date:  2014-11-30

9.  Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10 ng/mL?

Authors:  W F S Busato; G L Almeida; Jamylle Geraldo; F S Busato
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

10.  Carbonic anhydrase I as a new plasma biomarker for prostate cancer.

Authors:  Michiko Takakura; Akira Yokomizo; Yoshinori Tanaka; Michimoto Kobayashi; Giman Jung; Miho Banno; Tomohiro Sakuma; Kenjiro Imada; Yoshinao Oda; Masahiro Kamita; Kazufumi Honda; Tesshi Yamada; Seiji Naito; Masaya Ono
Journal:  ISRN Oncol       Date:  2012-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.